1.Construction and Application of Liver Injury Risk Prediction Model of Chinese Medicinals based on Indirect Toxicity
Guangdi MU ; Ming NIU ; Yunjuan GAO ; Chengzhao WU ; Fei TANG ; Xu ZHAO ; Xiaoyan ZHAN ; Zhaofang BAI ; Yuming GUO ; Xiaohe XIAO
Journal of Traditional Chinese Medicine 2023;64(17):1763-1770
ObjectiveTo explore and establish the liver injury risk prediction model of indirect toxicity of Chinese medicinals under the condition of compound formulas, and provide new ideas and methods for the study of evaluation of liver injury of Chinese medicinals based on indirect toxicity. MethodsTaking Buguzhi (Fructus Psoraleae) pre-parations as model drug, the combined Chinese medicinals with Buguzhi (Fructus Psoraleae) of high frequency are screened out, and their components and action targets were obtained through TCMSP, TCMIP and PharmMapper databases. The association strength value and risk value of Chinese medicinals that acted on the nuclear factor κB (NF-κB) pathway were analyzed. For those having greater values than the median association strength value and risk value were regarded as indirect Chinese medicinals of liver injury risk. In this way, a prediction model of liver injury risk of Chinese medicinals was constructed based on immune activation-related indirect liver injury process (taking NF-κB pathway as an example). And verification of the prediction model was performed using Heshouwu (Radix Polygoni Multiflori) preparations. ResultsThe prediction model of liver injury risk based on important immunoactivated pathway (taking NF-κB pathway as an example) found that Yinyanghuo (Herba Epimedii) (association strength value = 0.18, risk value = 0.25) was a Chinese medicinal with potential risk of indirect liver injury within Buguzhi (Fructus Psoraleae) prepartions, which may increase the risk of liver injury by positively regulating Bruton's tyrosine kinase (Btk) and protein kinase C theta (PKCθ) on NF-κB pathway. Further verification of prediction model by Heshouwu (Radix Polygoni Multiflori) preparations showed that Buguzhi (Fructus Psoraleae) (association strength value = 0.25, risk value = 0.33) and Tusizi (Semen Cuscutae) (Semen Cuscutae, association strength value = 0.34, risk value = 0.33) may increase the liver injury risk of Heshouzu. ConclusionThe liver injury risk prediction model of indirect toxicity of Chinese medicinals has been constructed in this study, providing metho-dological reference for the identification of Chinese medicinals of indirect liver injury risk under the condition of compound formulas.
2.Identification and analysis of the risk of liver-related adverse drug reaction in pregnant women
Guangdi MU ; Jiayi LI ; Yunjuan GAO ; Xu ZHAO ; Jiabo WANG ; Zhaofang BAI ; Xiaohe XIAO ; Yuming GUO
Journal of Clinical Hepatology 2022;38(8):1834-1838
Objective To investigate the potential medication risk by identifying and analyzing the features of liver-related adverse drug reaction (ADR) in pregnant women. Methods A retrospective study was performed for the reports on liver-related ADR in pregnant women from January 1, 2012 to December 31, 2016 in HILI Cloud (hilicloud.net). Main clinical features and medication rules were analyzed, and reporting odds ratio ( ROR ) was used to analyze the relative risk of related drugs. Results Methotrexate, mifepristone, and ritodrine were the high-frequency drugs reported for liver-related ADR in pregnant women and were mainly used for termination of ectopic pregnancy and treatment of hydatidiform mole. The relative risk analysis of liver-related ADR showed that in pregnant women, the use of methotrexate ( ROR =37.52, 95% confidence interval [ CI ]=31.35-44.89), progesterone ( ROR =7.33, 95% CI : 2.75-19.59), and dydrogesterone ( ROR =6.58, 95% CI : 2.20-19.69) was strongly associated with the risk of liver injury, and the association of methotrexate with the risk of liver injury in pregnant women was significantly stronger than that in non-pregnant women ( ROR =1.71, 95% CI : 1.47-4.36). Conclusion The potential risk of liver injury should be taken seriously in pregnant women using the drugs such as methotrexate and progesterone, so as to avoid serious adverse reactions.